On May 19, the Wall Street Journal revisited industry and patient relationships leading up to FDA approval of Sarepta’s eteplirsen. Chris Smith weighs in.
The world of orphan drugs is evolving quickly.
We keep our feet on the ground, our sleeves rolled up, and our ears open.
Let us share what we’ve learned and apply our thinking to your challenges.